Effect of treatment, during primary infection, on establishment and clearance of cellular reservoirs of HIV-1

Journal of Infectious Diseases

Volumn 191, Issue 9, 2005, Pages 1410-1418

  Strain, Matthew C ^a   Little, Susan J ^b   Daar, Eric S ^d,e   Havlir, Diane V ^f   Günthard, Huldrych F ^h   Lam, Ruby Y ^a   Daly, Otto A ^c   Nguyen, Juin ^c   Ignacio, Caroline C ^c   Spina, Celsa A ^c   Richman, Douglas D ^a,c   Wong, Joseph K ^a,c,g  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Antiviral Research Center

^c VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

^d HARBOR UCLA MEDICAL CENTER   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f SAN FRANCISCO GENERAL HOSPITAL   (United States)

^g SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

^h UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; AMPRENAVIR; ANTIRETROVIRUS AGENT; DIDANOSINE; EFAVIRENZ; HYDROXYUREA; INDINAVIR; LAMIVUDINE; LOPINAVIR; NELFINAVIR; NEVIRAPINE; RITONAVIR; STAVUDINE; VIRUS DNA; ZALCITABINE; ZIDOVUDINE;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DNA DEGRADATION; DRUG RESPONSE; ERADICATION THERAPY; EX VIVO STUDY; HALF LIFE TIME; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION CONTROL; LYMPHOCYTE ACTIVATION; PRIMARY INFECTION; PRIORITY JOURNAL; SEROCONVERSION; T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION; VIREMIA; VIRUS INFECTIVITY; VIRUS INHIBITION;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DNA, VIRAL; HIV SEROPOSITIVITY; HIV-1; HUMANS; KINETICS; TIME FACTORS;

EID: 20244376915     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/428777     Document Type: Article

References (59)

1. Wong JK, Hezareh M, Günthard HF, et al. Recovery of replication competent HIV despite prolonged suppression of plasma viremia. Science 1997; 278:1291-5.
2. Finzi D, Hermankova M, Pierson T, et al. Identification of a reservoir for HIV in patients on highly active antiretroviral therapy. Science 1997; 278:1295-300.
3. Chun TW, Carruth L, Finzi D, et al. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature 1997; 387:183-8.
4. Pomerantz RJ. Residual HIV-1 infection during antiretroviral therapy: the challenge of viral persistence. AIDS 2001; 15:1201-11.
5. Chun TW, Engel D, Berrey MM, Shea T, Corey L, Fauci AS. Early establishment of a pool of latently infected, resting CD4 T cells during primary HIV-1 infection. Proc Natl Acad Sci USA 1998; 95:8869-73.
6. Zhang L, Ramratnam B, Tenner-Racz K, et al. Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy. N Engl J Med 1999; 340:1605-13.
7. + T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat Med 1999; 5:512-7.
8. Ramratnam B, Mittler JE, Zhang L, et al. The decay of the latent reservoir of replication competent HIV-1 is inversely correlated with the extent of residual viral replication during prolonged anti-retroviral therapy. Nat Med 2000; 6:82-5.
9. Lori F, Jessen H, Lieberman J, et al. Treatment of HIV infection with hydroxyurea, didanosine, and a protease inhibitor before seroconversion is associated with normalized immune parameters and a limited viral reservoir. J Infect Dis 1999; 180:1827-32.
10. Strain MC, Günthard HF, Havlir DV, et al. Heterogeneous clearance rates of long-lived lymphocytes infected with HIV: intrinsic stability predicts lifelong persistence. Proc Natl Acad Sci USA 2003; 100:4819-24.
11. Blankson JN, Persaud D, Siliciano RF. The challenge of viral reservoirs in HIV-1 infection. Annu Rev Med 2002; 53:557-93.
12. Cone RW, Gowland P, Opravil M, Grob P, Ledergerber B, the Swiss AIDS Cohort. Levels of HIV-infected peripheral blood cells remain stable throughout the natural history of HIV-1 infection. Swiss HIV Cohort Study. AIDS 1998; 12:2253-60.
13. + T cell decline in human immunodeficiency virus (HIV) type 1- and HIV-2-infected individuals from Senegal, West Africa. J Infect Dis 2002; 185:905-14.
14. Perelson AS, Essunger P, Cao Y, et al. Decay characteristics of HIV-1 infected compartments during combination therapy. Nature 1997; 387:188-91.
15. Yerly S, Perneger TV, Vora S, Hirschel B, Perrin L. Decay of cell-associated HIV-1 DNA correlates with residual replication in patients treated during acute HIV-1 infection. AIDS 2000; 14:2805-12.
16. Little SJ, Holte S, Routy JP, et al. Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med 2002; 347:385-94.
17. Yerly S, Kaiser L, Perneger TV, et al. Time of initiation of antiretroviral therapy: impact on HIV-1 viraemia. AIDS 2000; 14:243-9.
18. Rosenberg ES, Billingsley JM, Caliendo AM, et al. Vigorous HIV-1 specific CD4 T cell responses associated with control of viremia. Science 1997; 278:1447-50.
19. - T T lymphocytes. Proc Natl Acad Sci USA 2000; 97:3382-7.
20. Altfeld M, Rosenberg ES, Shankarappa R, et al. Cellular immune responses and viral diversity in individuals treated during acute and early HIV-1 infection. J Exp Med 2001; 193:169-80.
21. Lori F, Lewis MG, Xu J, et al. Control of SIV rebound through structured treatment interruptions during early infection. Science 2000; 290:1591-3.
22. + lymphocytes in control of simian immunodeficiency virus infection and resistance to rechallenge after transient early antiretroviral treatment. J Virol 2001; 75:10187-99.
23. Lisziewicz J, Rosenberg E, Lieberman J, et al. Control of HIV despite the discontinuation of antiretroviral therapy. N Engl J Med 1999; 340:1683-4.
24. Rosenberg ES, Altfeld M, Poon SH, et al. Immune control of HIV-1 after early treatment of acute infection. Nature 2000; 407:523-6.
25. Zhang L, Chung C, Hu BS, et al. Genetic characterization of rebounding HIV-1 after cessation of highly active antiretroviral therapy. J Clin Invest 2000; 106:839-45.
26. + T-cell responses do not predict viral growth and clearance rates during structured intermittent antiretroviral therapy. J Virol 2002; 76:10169-76.
27. Oxenius A, Price DA, Gunthard HF, et al. Stimulation of HIV-specific cellular immunity by structured treatment interruption fails to enhance viral control in chronic HIV infection. Proc Natl Acad Sci USA 2002; 99:13747-52.
28. Ortiz GM, Wellons M, Brancato J, et al. Structured antiretroviral treatment interruptions in chronically HIV-1-infected subjects. Proc Natl Acad Sci USA 2001; 98:13288-93.
29. Gulick RM, Mellors JW, Havlir D, et al. Treatment with a combination of indinavir, zidovudine and lamivudine in HIV-infected adults with prior antiretroviral use. N Engl J Med 1997; 337:734-9.
30. Ruiz N, Riddler S, Dupont Merck Study Group. A double-blind pilot study to evaluate the antiretroviral activity, tolerability of DMP 266 in combination with indinivir (cohort III) [abstract LB2/206]. In: Program and abstracts of the 4th Conference on Retroviruses and Opportunistic Infections (Washington DC). Alexandria, VA: Foundation for Retrovirology and Human Health, 1997.
31. Christopherson C, Kidane Y, Conway B, Krowka J, Sheppard H, Kwok S. PCR-based assay to quantify human immunodeficiency virus type 1 DNA in peripheral blood mononuclear cells. J Clin Microbiol 2000; 38:630-4.
32. Spina CA, Guatelli JC, Richman DD. Establishment of a stable, inducible form of HIV-1 DNA in quiescent CD4 lymphocytes in vitro. J Virol 1995; 69:2977-88.
33. Taswell C. Limiting dilution assays for the determination of immunocompetent cell frequencies. I. Data analysis. J Immunol 1981; 126:1614-9.
34. + T cell demographics and dynamics in lymphatic tissues. Annu Rev Immunol 1999; 17:625-6.
35. Havlir DV, Bassett R, Gilbert P, et al. Prevalence and predictive value of intermittent viremia with combination HIV therapy. JAMA 2001; 286:224-6.
36. + T cells in acute human immunodeficiency virus type 1 infection. J Infect Dis 2000; 182:1636-42.
37. Haase AT, Henry K, Zapancic M, et al. Quantitative image analysis of HIV-1 infection in lymphoid tissue. Science 1996; 274:985-9.
38. Schacker T, Little S, Connick E, et al. Rapid accumulation of human immunodeficiency virus (HIV) in lymphatic tissue reservoirs during acute and early HIV infection: implications for timing of antiretroviral therapy. J Infect Dis 2000; 181:354-7.
39. + T cells. Nature 2002; 417:95-8.
40. Cossarizza A, Ortolani C, Mussini C, et al. Massive activation of immune cells with an intact T cell repertoire in acute human immunodeficiency virus syndrome. J Infect Dis 1995; 172:105-12.
41. Barcellini W, Rizzardi GP, Poli G, et al. Cytokines and soluble receptor changes in the transition from primary to early chronic HIV type 1 infection. AIDS Res Hum Retroviruses 1996; 12:325-31.
42. Carcelain G, Blanc C, Leibowitch J, et al. T cell changes after combined nucleoside analogue therapy in HIV primary infection. AIDS 1999; 13:1077-81.
43. Kaufmann GR, Zaunders JJ, Cunningham P, et al. Rapid restoration of CD4 T cell subsets in subjects receiving antiretroviral therapy during primary HIV-1 infection. AIDS 2000; 14:2643-51.
44. Donovan RM, Bush CE, Smereck SM, Baxa DM, Markowitz NP, Saravolatz LD. Rapid decrease in unintegrated HIV DNA after the initiation of nucleoside therapy. J Infect Dis 1994; 170:202-5.
45. Butler SL, Johnson EP, Bushman FD. Human immunodeficiency virus cDNA metabolism: notable stability of two-long terminal repeat circles. J Virol 2002; 76:3739-47.
46. Pierson TC, Kieffer TL, Ruff CT, Buck C, Gange SJ, Siliciano RF. Intrinsic stability of episomal circles formed during human immunodeficiency virus type 1 replication. J Virol 2002; 76:4138-44.
47. Fischer M, Trkola A, Joos B, et al. Shifts in cell-associated HIV-1 RNA but not in episomal HIV-1 DNA correlate with new cycles of HIV-1 infection in vivo. Antivir Ther 2003; 8:97-104.
48. Opravil M, Cone RW, Fischer M, et al. Effects of early antiretroviral treatment on HIV-1 RNA in blood and lymphoid tissue: a randomized trial of double versus triple therapy. Swiss HIV Cohort Study. J Acquir Immune Defic Syndr 2000; 23:17-25.
49. Muller V, Vigueras-Gomez JF, Bonhoeffer S. Decelerating decay of latently infected cells during prolonged therapy for human immunodeficiency virus type 1 infection. J Virol 2002; 76:8963-5.
50. + lymphocytes by human immunodeficiency virus type 1 in vivo. J Virol 2001; 75:4091-102.
51. Brooks DG, Kitchen SG, Kitchen CM, Scripture-Adams DD, Zack JA. Generation of HIV latency during thymopoiesis. Nat Med 2001; 7:459-64.
52. Sonza S, Mutimer HP, Oelrichs R, et al. Monocytes harbour replication-competent, non-latent HIV-1 in patients on highly active antiretroviral therapy. AIDS 2001; 15:17-22.
53. Valentin A, Rosati M, Patenaude DJ, et al. Persistent HIV-1 infection of natural killer cells in patients receiving highly active antiretroviral therapy. Proc Natl Acad Sci USA 2002; 99:7015-20.
54. + T cells. Nat Med 2003; 9:727-8.
55. Ortiz GM, Nixon DF, Trkola A, et al. HIV-1-specific immune responses in subjects who temporarily contain virus replication after discontinuation of highly active antiretroviral therapy. J Clin Invest 1999; 104:R13-8.
56. Kulkosky J, Pomerantz RJ. Approaching eradication of highly active antiretroviral therapy-persistent human immunodeficiency virus type 1 reservoirs with immune activation therapy. Clin Infect Dis 2002; 35:1520-6.
57. Robbins GK, Addo MM, Troung H, et al. Augmentation of HIV-1-specific T helper cell responses in chronic HIV-1 infection by therapeutic immunization. AIDS 2003; 17:1121-6.
58. Grossman Z, Feinberg MB, Paul WE. Multiple modes of cellular activation and virus transmission in HIV infection: a role for chronically and latently infected cells in sustaining viral replication. Proc Natl Acad Sci USA 1998; 95:6314-9.
59. Flandre P, Peytavin G, Meiffredy V, et al. Adherence to antiretroviral therapy and outcomes in HIV-infected patients enrolled in an induction/maintenance randomized trial. Antivir Ther 2002; 7:113-21.